Open AccessExpression of p53, DCC, and HER‐2/neu in Mucinous Carcinoma of the Breast
Author(s) -
Hsu YungHsiang,
Shaw ChengKuang
Publication year - 2005
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1016/s1607-551x(09)70188-3
Subject(s) - mucinous carcinoma , medicine , progesterone receptor , breast cancer , estrogen receptor , carcinoma , lymph node , pathology , lymph node metastasis , breast carcinoma , ductal carcinoma , metastasis , oncology , cancer , adenocarcinoma
We investigated the clinicopathologic and oncoprotein expression characteristics of 11 pure mucinous and 76 non‐mucinous infiltrating ductal carcinomas in the human female breast. We compared patient age, tumor size, axillary lymph node status, and the expression of estrogen receptor (ER), progesterone receptor (PR), deleted‐in‐colon cancer (DCC), HER‐2/neu, and p53. Mucinous carcinoma with axillary lymph node metastasis occurs less frequently than non‐mucinous carcinoma (0% vs 63.1%; p = 0.0018). Compared with the non‐mucinous type, mucinous carcinoma specimens have more DCC expression (100% vs 48.7%; p = 0.0027) and more ER expression (90.9% vs 26.9%; p = 0.0023), but less HER‐2/neu overexpression (0% vs 38.1%; p = 0.0302). We confirmed that mucinous carcinoma samples from the breast reveal distinct clinicopathologic and oncoprotein expression features compared with non‐mucinous carcinoma and, therefore, it seems reasonable to suggest different biologic characteristics and manifestations.